Limits...
CD147/EMMPRIN overexpression and prognosis in cancer: A systematic review and meta-analysis

View Article: PubMed Central - PubMed

ABSTRACT

CD147/EMMPRIN (extracellular matrix metalloproteinase inducer) plays an important role in tumor progression and a number of studies have suggested that it is an indicator of tumor prognosis. This current meta-analysis systematically reevaluated the predictive potential of CD147/EMMPRIN in various cancers. We searched PubMed and Embase databases to screen the literature. Fixed-effect and random-effect meta-analytical techniques were used to correlate CD147 expression with outcome measures. A total of 53 studies that included 68 datasets were eligible for inclusion in the final analysis. We found a significant association between CD147/EMMPRIN overexpression and adverse tumor outcomes, such as overall survival, disease-specific survival, progression-free survival, metastasis-free survival or recurrence-free survival, irrespective of the model analysis. In addition, CD147/EMMPRIN overexpression predicted a high risk for chemotherapy drugs resistance. CD147/EMMPRIN is a central player in tumor progression and predicts a poor prognosis, including in patients who have received chemo-radiotherapy. Our results provide the evidence that CD147/EMMPRIN could be a potential therapeutic target for cancers.

No MeSH data available.


Related in: MedlinePlus

Qualitative meta-analysis of the association between CD147/EMMPRIN over-expression and PFS/MFS/RFS in cancer patients.Panel (A) represents the overall association of CD147/EMMPRIN positive expression with worse PFS/MFS/RFS in multivariate model; panel (B) depicts similar association in univariate model.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5016850&req=5

f4: Qualitative meta-analysis of the association between CD147/EMMPRIN over-expression and PFS/MFS/RFS in cancer patients.Panel (A) represents the overall association of CD147/EMMPRIN positive expression with worse PFS/MFS/RFS in multivariate model; panel (B) depicts similar association in univariate model.

Mentions: Analysis of 19 studies, with a total of 2,472 patients, showed that CD147/EMMPRIN expression was associated with worse PFS/MFS/RFS, both in multivariate (meta-HR = 2.32; 95% CI: 1.67–3.21) and univariate (meta-HR = 2.18; 95% CI: 1.30–3.63) models (Table 3 and Fig. 4A,B). Moreover, the HR estimates derived specifically from the solid tumors by both models showed a similar pattern of association (multivariate: meta-HR = 2.26; 95% CI: 1.61–3.18; univariate: meta-HR = 2.18; 95% CI: 1.30–3.63). Exclusive analysis of non-solid tumors by a multivariate model suggested a significant association (meta-HR = 3.52; 95% CI: 1.18–10.5) (Table 4).


CD147/EMMPRIN overexpression and prognosis in cancer: A systematic review and meta-analysis
Qualitative meta-analysis of the association between CD147/EMMPRIN over-expression and PFS/MFS/RFS in cancer patients.Panel (A) represents the overall association of CD147/EMMPRIN positive expression with worse PFS/MFS/RFS in multivariate model; panel (B) depicts similar association in univariate model.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5016850&req=5

f4: Qualitative meta-analysis of the association between CD147/EMMPRIN over-expression and PFS/MFS/RFS in cancer patients.Panel (A) represents the overall association of CD147/EMMPRIN positive expression with worse PFS/MFS/RFS in multivariate model; panel (B) depicts similar association in univariate model.
Mentions: Analysis of 19 studies, with a total of 2,472 patients, showed that CD147/EMMPRIN expression was associated with worse PFS/MFS/RFS, both in multivariate (meta-HR = 2.32; 95% CI: 1.67–3.21) and univariate (meta-HR = 2.18; 95% CI: 1.30–3.63) models (Table 3 and Fig. 4A,B). Moreover, the HR estimates derived specifically from the solid tumors by both models showed a similar pattern of association (multivariate: meta-HR = 2.26; 95% CI: 1.61–3.18; univariate: meta-HR = 2.18; 95% CI: 1.30–3.63). Exclusive analysis of non-solid tumors by a multivariate model suggested a significant association (meta-HR = 3.52; 95% CI: 1.18–10.5) (Table 4).

View Article: PubMed Central - PubMed

ABSTRACT

CD147/EMMPRIN (extracellular matrix metalloproteinase inducer) plays an important role in tumor progression and a number of studies have suggested that it is an indicator of tumor prognosis. This current meta-analysis systematically reevaluated the predictive potential of CD147/EMMPRIN in various cancers. We searched PubMed and Embase databases to screen the literature. Fixed-effect and random-effect meta-analytical techniques were used to correlate CD147 expression with outcome measures. A total of 53 studies that included 68 datasets were eligible for inclusion in the final analysis. We found a significant association between CD147/EMMPRIN overexpression and adverse tumor outcomes, such as overall survival, disease-specific survival, progression-free survival, metastasis-free survival or recurrence-free survival, irrespective of the model analysis. In addition, CD147/EMMPRIN overexpression predicted a high risk for chemotherapy drugs resistance. CD147/EMMPRIN is a central player in tumor progression and predicts a poor prognosis, including in patients who have received chemo-radiotherapy. Our results provide the evidence that CD147/EMMPRIN could be a potential therapeutic target for cancers.

No MeSH data available.


Related in: MedlinePlus